Pelvic Exenteration with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS + HIPEC) for Rectal Cancer-Case Series with Review of Literature

Rajesh S Shinde; Rajgopal Acharya; Naveena An Kumar; Sohan Solanki; Ashwin Desouza; Avanish Saklani

doi:10.1007/s13193-019-00882-0

Pelvic Exenteration with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS + HIPEC) for Rectal Cancer-Case Series with Review of Literature

Indian J Surg Oncol. 2019 Feb;10(Suppl 1):80-83. doi: 10.1007/s13193-019-00882-0. Epub 2019 Jan 23.

Authors

Rajesh S Shinde¹, Rajgopal Acharya¹, Naveena An Kumar¹, Sohan Solanki², Ashwin Desouza¹, Avanish Saklani¹

Affiliations

¹ 1Colorectal Services, Department of Surgical oncology, Tata Memorial Hospital, Ernest Borges Marg, Parel, Mumbai, 400 012 India.
² 2Department of Anaesthesia and Critical Care, Tata Memorial Hospital, Mumbai, India.

Abstract

Incidence of synchronous peritoneal metastases (PM) in colorectal cancer is approximately 5%, with another 5% of the patients develop metachronous PM. Colorectal PM has been hypothesized to be a loco-regional disease rather than a systemic spread, and cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been considered as a viable treatment option. Pelvic exenteration is an established treatment option for locally advanced rectal cancer, but it is associated with significant morbidity. However, there are no studies evaluating the role of such procedure probably because the majority consider it as an exclusion criterion. Here, we present our experience with three cases of locally advanced rectal cancer with PM, treated successfully with pelvic exenteration and CRS-HIPEC.

Keywords: CRS; HIPEC; Pelvic exenteration; Rectal cancer.

Publication types

Review